| 1 |
35063965 | Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. | 2022 Jan 21 |
7 |
| 2 |
35452083 | Shall We Dance: Evolving Partnerships of Targeted Therapies for AML. | 2022 Apr 22 |
1 |
| 3 |
35580565 | Gilteritinib in isolated breast relapse of FLT3positive acute myeloid leukemia: a case report and review of literature. | 2022 May 17 |
2 |
| 4 |
33368797 | Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML. | 2021 Feb |
1 |
| 5 |
33853292 | A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. | 2021 Aug 1 |
2 |
| 6 |
31488557 | Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. | 2020 Jun |
1 |
| 7 |
32085993 | A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. | 2020 Apr |
1 |
| 8 |
32391254 | Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy. | 2020 |
1 |
| 9 |
32425393 | Azacytidine in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia Presenting with Pneumonia: A Case Series. | 2020 Apr |
1 |
| 10 |
33282167 | ERRATUM: A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant. | 2020 Nov 16 |
1 |
| 11 |
30915202 | A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant. | 2019 Feb 19 |
1 |
| 12 |
31069015 | Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia. | 2019 Apr 2 |
2 |
| 13 |
31203997 | Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia. | 2019 Jun |
2 |
| 14 |
31672129 | The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report. | 2019 Oct 31 |
1 |
| 15 |
30028037 | Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. | 2018 Sep |
5 |
| 16 |
30275526 | Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. | 2018 Dec |
1 |
| 17 |
27893163 | Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. | 2017 Apr |
3 |
| 18 |
28159598 | Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. | 2017 May |
2 |
| 19 |
28196687 | Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy. | 2017 Apr |
1 |
| 20 |
28746590 | Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases. | 2017 Jul-Sep |
3 |
| 21 |
29312564 | Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations. | 2017 Dec 12 |
4 |
| 22 |
25776192 | A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. | 2015 Jul |
1 |
| 23 |
25820334 | Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia. | 2015 Jul |
1 |
| 24 |
26547689 | Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. | 2015 Nov 7 |
1 |
| 25 |
23613521 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. | 2013 Jun 6 |
2 |